Table 2 Area under the receiver operating curve for vedolizumab trough level cut-offs associated with effectiveness outcomes.

From: Association of early vedolizumab trough levels with clinical, biochemical, endoscopic response and drug optimization during maintenance therapy in patients with inflammatory bowel diseases

Outcomes

Week

Cut-off VTL, µg/mL

AUC (95% CI)

Sensitivity (%)

Specificity (%)

PPV (%)

NPV (%)

CSF-CREM at W14 in UC

2

41.0

0.810 (0.604–1.000)

80.0

81.0

50.0

94.4

BioRES[CRP] at W14 in CD

6

19.1

0.733 (0.539–0.928)

88.9

70.0

57.1

93.3

14

4.4

0.739 (0.530–0.948)

77.8

75.0

58.3

88.2

BioRES[FC] at W54 in CD

14

5.3

0.859 (0.730–0.988)

100.0

80.8

54.5

100.0

BioRES[FC] at W14 in UC

2

41.0

0.815 (0.636–0.994)

71.4

82.4

62.5

87.5

6

31.3

0.874 (0.733–1.000)

100.0

70.6

58.3

100.0

14

9.8

0.849 (0.692–1.000)

100.0

70.6

58.3

100.0

EH at W14 in UC

2

41.0

0.739 (0.527–0.951)

70.0

83.3

70.0

83.3

6

38.1

0.744 (0.540–0.949)

70.0

77.8

63.6

82.4

Drug optimization in CD

14

4.6

0.765 (0.613–0.917)

83.3

66.7

68.2

83.3

  1. AUC, area under the receiver operating curve; BioRES[CRP], biochemical response based on C-reactive protein; BioRES[FC], biochemical response based on fecal calprotectin; CD, Crohn’s disease; CI, confidence interval; CSF-CREM, corticosteroid-free clinical remission; EH, endoscopic healing; NPV, negative predictive value; PPV, positive predictive value; UC, ulcerative colitis; VTL, vedolizumab trough level; W, week.
Back to article page